Predialysis chronic kidney disease correlates with increased risk of pyogenic liver abscess: a population-based cohort study

Lai, Shih‐Wei; Lin, Cheng‐Li; Liao, Kuan‐Fu

doi:10.1111/eci.12793

Cited by 6 publications

(4 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All comorbidities were diagnosed based on ICD-9 codes. The validity of ICD-9 codes has been discussed in previous studies ( Hung et al, 2016 ; Lai et al, 2016 , 2017a , b ; Liao et al, 2016a , b , 2017a , b ; Shen et al, 2016 ; Wong et al, 2016 ; Lin C.M. et al, 2017 ; Hung et al, 2017 ).…”

Section: Methodsmentioning

confidence: 94%

Case-Control Study Examining the Association between Selective Serotonin Reuptake Inhibitors Use and Hepatocellular Carcinoma

et al. 2017

Self Cite

View full text Add to dashboard Cite

Objectives: The purpose of the study was to assess the relationship between selective serotonin reuptake inhibitors use and hepatocellular carcinoma in Taiwan.Methods: Using the database of the Taiwan National Health Insurance Program, we conducted a case-control study to identify 4901 subjects aged 20 years and more with newly diagnosed hepatocellular carcinoma in 2000–2013 as the cases. We randomly selected 19604 subjects aged 20 years and more without hepatocellular carcinoma as the controls. Both cases and controls were matched with sex and age. Ever use of selective serotonin reuptake inhibitors was defined as a subject who had at least a prescription for selective serotonin reuptake inhibitors before index date. Never use was defined as a subject who never had a prescription for selective serotonin reuptake inhibitors before index date. The odds ratio (OR) and 95% confidence interval (CI) for hepatocellular carcinoma associated with selective serotonin reuptake inhibitors use was estimated by the multivariable logistic regression model.Results: Among subjects with any one of the comorbid conditions associated with hepatocellular carcinoma, the adjusted OR of hepatocellular carcinoma was 0.89 (95% CI 0.75, 1.06) for subjects with ever use of selective serotonin reuptake inhibitors, comparing with never use.Conclusion: The findings indicate that among subjects with any one of the comorbid conditions associated with hepatocellular carcinoma, no significant association can be detected between selective serotonin reuptake inhibitors use and hepatocellular carcinoma.

show abstract

Section: Methodsmentioning

confidence: 94%

Case-Control Study Examining the Association between Selective Serotonin Reuptake Inhibitors Use and Hepatocellular Carcinoma

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous studies showed that cellular dysfunction of T cells and B cells, and phagocytic defect of neutrophils observed in chronic kidney disease might play the key roles in the involvement of developing herpes zoster 29‐31 . Some epidemiological studies showed that patients with predialysis chronic kidney were at risk of developing pneumonia, pyogenic liver abscess and pulmonary tuberculosis owing to declined immune functions 6‐8 . From a view of prevention medicine, vaccination and chemoprophylaxis are both strategies for primary prevention.…”

Section: Discussionmentioning

confidence: 99%

“…Meanwhile, impaired immune functions are commonly noted in patients with chronic kidney disease, including declined functions of T cells, B cells and neutrophils 4 . Therefore, patients with chronic kidney disease are at risk of various infectious diseases including pneumonia, pyogenic liver abscess and pulmonary tuberculosis 5‐8 …”

Section: Introductionmentioning

confidence: 99%

Risk of herpes zoster among patients with predialysis chronic kidney disease in a cohort study in Taiwan

Lai

Kuo²,

Lin

et al. 2020

Int. J. Clin. Pract.

Self Cite

View full text Add to dashboard Cite

Background/Objective Patients on chronic dialysis are at risk of developing herpes zoster, but little systematic research focuses on the association between predialysis chronic kidney disease and herpes zoster. The objective of the study was to explore the association between predialysis chronic kidney disease and herpes zoster in Taiwan. Methods A nation‐based retrospective cohort study was performed using the 2005‐2012 database of the Taiwan National Health Insurance Program. There were 16 655 subjects aged 20‐84 years with newly diagnosed predialysis chronic kidney disease as the study group and 33 310 randomly selected subjects without chronic kidney disease as the comparison group. Both groups were matched with sex, age, comorbidities and the year of the index date. The incidence rates of herpes zoster in both groups were calculated. The multivariable Cox proportional hazards regression model was used to estimate the hazard ratio (HR) and 95% confidence interval (CI) for herpes zoster associated with predialysis chronic kidney disease. Results The overall incidence rate of herpes zoster was 1.4‐fold higher in the predialysis chronic kidney disease group than that in the non‐chronic kidney disease group (8.76 vs 6.27 per 1000 person‐years, 95% CI 1.27‐1.54; P < .001). After controlling for co‐variables, the adjusted HR of herpes zoster was 1.38 (95% CI 1.25‐1.53; P < .001) for subjects with predialysis chronic kidney disease compared with non‐chronic kidney disease subjects. The adjusted HR increased to 1.65 for subjects with predialysis chronic kidney disease and with any comorbidity (95% CI 1.42‐1.92; P < .001). Conclusions Patients with predialysis chronic kidney disease correlate with approximately 1.4‐fold increased hazard of developing herpes zoster.

show abstract

“…Comorbidities potentially related to ischemic cerebrovascular disease before index date were identified as follows: alcohol-related disease, atrial fibrillation, chronic kidney disease, chronic obstructive pulmonary disease, coronary artery disease, hyperlipidemia, and hypertension. Based on the ICD-9 codes, the diagnosis validity of comorbidities was discussed in previous studies ( Lai et al, 2017a , b , c , d , e , f ; Liao et al, 2017e ; Lin et al, 2017b , c ).…”

Section: Methodsmentioning

confidence: 99%

Dipeptidyl Peptidase-4 Inhibitors Use and Relative Risk of Ischemic Cerebrovascular Disease in Type 2 Diabetic Patients in a Case-Control Study

et al. 2017

Self Cite

View full text Add to dashboard Cite

Background and Objectives: Limited research focuses on the risk of ischemic cerebrovascular disease associated with use of dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) in patients with type 2 diabetes mellitus in Taiwan. This study aimed to investigate the association between DPP-4 inhibitors use and the first episode of ischemic cerebrovascular disease.Methods: We designed a case-control study using the database of the Taiwan National Health Insurance Program. There were 1999 type 2 diabetic subjects aged 20–84 years with the first episode of ischemic cerebrovascular disease from 2000 to 2013 as the cases, and 7996 sex- and age-matched, randomly selected type 2 diabetic subjects aged 20–84 years without any type of cerebrovascular diseases as the matched controls. We estimated the odds ratio (OR) and 95% confidence interval (CI) of ischemic cerebrovascular disease associated with cumulative duration of DPP-4 inhibitors use by the multivariable logistic regression model.Results: After adjustment for confounding variables, the adjusted OR of ischemic cerebrovascular disease was 0.96 (95% CI 0.95, 0.97) in subjects with ever use of DPP-4 inhibitors as increase in use duration for every 1 month, compared with never use. The sub-analysis disclosed that the adjusted ORs of ischemic cerebrovascular disease were 1.57 (95% CI 1.36, 1.80) for subjects with cumulative duration of DPP-4 inhibitors use <1 year, and 0.70 (95% CI 0.57, 0.87) for subjects with cumulative duration of DPP-4 inhibitors use ≥1 year, compared with never use.Conclusion: Our findings suggest that DPP-4 inhibitors use correlates with relative risk reduction of the first episode of ischemic cerebrovascular disease in type 2 diabetic patients in a duration-dependent response. The beneficial effect will be marked when DPP-4 inhibitors use is ≥1 year.

show abstract

Predialysis chronic kidney disease correlates with increased risk of pyogenic liver abscess: a population-based cohort study

Abstract: Predialysis chronic kidney disease is associated with 1·5-fold increased risk of pyogenic liver abscess. There seem to be a synergistic effect on the risk of pyogenic liver abscess between predialysis chronic kidney disease and comorbidities.

Cited by 6 publications

References 52 publications

Case-Control Study Examining the Association between Selective Serotonin Reuptake Inhibitors Use and Hepatocellular Carcinoma

Case-Control Study Examining the Association between Selective Serotonin Reuptake Inhibitors Use and Hepatocellular Carcinoma

Risk of herpes zoster among patients with predialysis chronic kidney disease in a cohort study in Taiwan

Dipeptidyl Peptidase-4 Inhibitors Use and Relative Risk of Ischemic Cerebrovascular Disease in Type 2 Diabetic Patients in a Case-Control Study

Contact Info

Product

Resources

About